Cost-effectiveness analysis of gumarontinib versus savolitinib for the treatment of advanced or metastatic NSCLC with MET exon 14 skipping mutations in China using partitioned survival model
Background and objectivesBoth gumarontinib and savolitinib have demonstrated efficacy in treating non-small-cell lung cancer (NSCLC) with tumors harboring mesenchymal–epithelial transition factor gene exon 14 (METex14) skipping. However, the comparison of their efficacy and pharmacoeconomics profile...
Saved in:
| Main Authors: | , , , , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
Frontiers Media S.A.
2025-01-01
|
| Series: | Frontiers in Pharmacology |
| Subjects: | |
| Online Access: | https://www.frontiersin.org/articles/10.3389/fphar.2025.1400422/full |
| Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
| _version_ | 1832589950074224640 |
|---|---|
| author | Gang Fang Zhipeng Pi Yiping An Xinxin Cao Wei Li Wei Li Xiangjun Zhu Jinxi Ding Jinxi Ding |
| author_facet | Gang Fang Zhipeng Pi Yiping An Xinxin Cao Wei Li Wei Li Xiangjun Zhu Jinxi Ding Jinxi Ding |
| author_sort | Gang Fang |
| collection | DOAJ |
| description | Background and objectivesBoth gumarontinib and savolitinib have demonstrated efficacy in treating non-small-cell lung cancer (NSCLC) with tumors harboring mesenchymal–epithelial transition factor gene exon 14 (METex14) skipping. However, the comparison of their efficacy and pharmacoeconomics profiles remains limited. This study aims to evaluate the cost-effectiveness of gumarontinib versus savolitinib for the treatment of METex14 skipping NSCLC in China.MethodsA 3-state partitioned survival model (PSM) was developed with lifetime horizon from the perspective of Chinese healthcare system. Survival inputs were based on an unanchored matching-adjusted indirect comparison using individual patient data from GLORY trial to adjust for patient characteristics in NCT02897479. Costs and outcomes were discounted at an annual rate of 5%. Sensitivity and scenario analyses were conducted to explore model uncertainty.ResultsGumarontinib gained an additional 0.10 QALYs at an incremental cost of $1,893 compared to savolitinib, resulting in the ICERs of $19,243/QALY, which is below the threshold of 3 times the GDP per capita in China ($35,007 per capita in 2022). Sensitivity and scenario analyses confirmed the robustness of the base-case results.ConclusionGumarontinib is a cost-effective option compared to savolitinib for METex14 skipping NSCLC in China. |
| format | Article |
| id | doaj-art-f03b4b7a52dc428bb08b42a69adde2f8 |
| institution | Kabale University |
| issn | 1663-9812 |
| language | English |
| publishDate | 2025-01-01 |
| publisher | Frontiers Media S.A. |
| record_format | Article |
| series | Frontiers in Pharmacology |
| spelling | doaj-art-f03b4b7a52dc428bb08b42a69adde2f82025-01-24T05:21:18ZengFrontiers Media S.A.Frontiers in Pharmacology1663-98122025-01-011610.3389/fphar.2025.14004221400422Cost-effectiveness analysis of gumarontinib versus savolitinib for the treatment of advanced or metastatic NSCLC with MET exon 14 skipping mutations in China using partitioned survival modelGang Fang0Zhipeng Pi1Yiping An2Xinxin Cao3Wei Li4Wei Li5Xiangjun Zhu6Jinxi Ding7Jinxi Ding8School of International Pharmaceutical Business, China Pharmaceutical University, Nanjing, ChinaSchool of International Pharmaceutical Business, China Pharmaceutical University, Nanjing, ChinaSchool of International Pharmaceutical Business, China Pharmaceutical University, Nanjing, ChinaSchool of International Pharmaceutical Business, China Pharmaceutical University, Nanjing, ChinaSchool of International Pharmaceutical Business, China Pharmaceutical University, Nanjing, ChinaPharmaceutical Market Access Policy Research Center, China Pharmaceutical University, Nanjing, ChinaJiangsu Health Development Research Center, Nanjing, ChinaSchool of International Pharmaceutical Business, China Pharmaceutical University, Nanjing, ChinaPharmaceutical Market Access Policy Research Center, China Pharmaceutical University, Nanjing, ChinaBackground and objectivesBoth gumarontinib and savolitinib have demonstrated efficacy in treating non-small-cell lung cancer (NSCLC) with tumors harboring mesenchymal–epithelial transition factor gene exon 14 (METex14) skipping. However, the comparison of their efficacy and pharmacoeconomics profiles remains limited. This study aims to evaluate the cost-effectiveness of gumarontinib versus savolitinib for the treatment of METex14 skipping NSCLC in China.MethodsA 3-state partitioned survival model (PSM) was developed with lifetime horizon from the perspective of Chinese healthcare system. Survival inputs were based on an unanchored matching-adjusted indirect comparison using individual patient data from GLORY trial to adjust for patient characteristics in NCT02897479. Costs and outcomes were discounted at an annual rate of 5%. Sensitivity and scenario analyses were conducted to explore model uncertainty.ResultsGumarontinib gained an additional 0.10 QALYs at an incremental cost of $1,893 compared to savolitinib, resulting in the ICERs of $19,243/QALY, which is below the threshold of 3 times the GDP per capita in China ($35,007 per capita in 2022). Sensitivity and scenario analyses confirmed the robustness of the base-case results.ConclusionGumarontinib is a cost-effective option compared to savolitinib for METex14 skipping NSCLC in China.https://www.frontiersin.org/articles/10.3389/fphar.2025.1400422/fullcost-effectiveness analysisMETex14non-small-cell lung cancergumarontinibsavolitinibMAIC |
| spellingShingle | Gang Fang Zhipeng Pi Yiping An Xinxin Cao Wei Li Wei Li Xiangjun Zhu Jinxi Ding Jinxi Ding Cost-effectiveness analysis of gumarontinib versus savolitinib for the treatment of advanced or metastatic NSCLC with MET exon 14 skipping mutations in China using partitioned survival model Frontiers in Pharmacology cost-effectiveness analysis METex14 non-small-cell lung cancer gumarontinib savolitinib MAIC |
| title | Cost-effectiveness analysis of gumarontinib versus savolitinib for the treatment of advanced or metastatic NSCLC with MET exon 14 skipping mutations in China using partitioned survival model |
| title_full | Cost-effectiveness analysis of gumarontinib versus savolitinib for the treatment of advanced or metastatic NSCLC with MET exon 14 skipping mutations in China using partitioned survival model |
| title_fullStr | Cost-effectiveness analysis of gumarontinib versus savolitinib for the treatment of advanced or metastatic NSCLC with MET exon 14 skipping mutations in China using partitioned survival model |
| title_full_unstemmed | Cost-effectiveness analysis of gumarontinib versus savolitinib for the treatment of advanced or metastatic NSCLC with MET exon 14 skipping mutations in China using partitioned survival model |
| title_short | Cost-effectiveness analysis of gumarontinib versus savolitinib for the treatment of advanced or metastatic NSCLC with MET exon 14 skipping mutations in China using partitioned survival model |
| title_sort | cost effectiveness analysis of gumarontinib versus savolitinib for the treatment of advanced or metastatic nsclc with met exon 14 skipping mutations in china using partitioned survival model |
| topic | cost-effectiveness analysis METex14 non-small-cell lung cancer gumarontinib savolitinib MAIC |
| url | https://www.frontiersin.org/articles/10.3389/fphar.2025.1400422/full |
| work_keys_str_mv | AT gangfang costeffectivenessanalysisofgumarontinibversussavolitinibforthetreatmentofadvancedormetastaticnsclcwithmetexon14skippingmutationsinchinausingpartitionedsurvivalmodel AT zhipengpi costeffectivenessanalysisofgumarontinibversussavolitinibforthetreatmentofadvancedormetastaticnsclcwithmetexon14skippingmutationsinchinausingpartitionedsurvivalmodel AT yipingan costeffectivenessanalysisofgumarontinibversussavolitinibforthetreatmentofadvancedormetastaticnsclcwithmetexon14skippingmutationsinchinausingpartitionedsurvivalmodel AT xinxincao costeffectivenessanalysisofgumarontinibversussavolitinibforthetreatmentofadvancedormetastaticnsclcwithmetexon14skippingmutationsinchinausingpartitionedsurvivalmodel AT weili costeffectivenessanalysisofgumarontinibversussavolitinibforthetreatmentofadvancedormetastaticnsclcwithmetexon14skippingmutationsinchinausingpartitionedsurvivalmodel AT weili costeffectivenessanalysisofgumarontinibversussavolitinibforthetreatmentofadvancedormetastaticnsclcwithmetexon14skippingmutationsinchinausingpartitionedsurvivalmodel AT xiangjunzhu costeffectivenessanalysisofgumarontinibversussavolitinibforthetreatmentofadvancedormetastaticnsclcwithmetexon14skippingmutationsinchinausingpartitionedsurvivalmodel AT jinxiding costeffectivenessanalysisofgumarontinibversussavolitinibforthetreatmentofadvancedormetastaticnsclcwithmetexon14skippingmutationsinchinausingpartitionedsurvivalmodel AT jinxiding costeffectivenessanalysisofgumarontinibversussavolitinibforthetreatmentofadvancedormetastaticnsclcwithmetexon14skippingmutationsinchinausingpartitionedsurvivalmodel |